China
Africa
Explore chapters and articles related to this topic
Data-Driven and Patient-Centred Health Systems
Published in Disa Lee Choun, Anca Petre, Digital Health and Patient Data, 2023
The country drew attention during the Covid-19 pandemic when it struck a deal with pharmaceutical company Pfizer to receive vaccines in exchange for health data.6 As stated by the agreement, Israel allowed Pfizer to access its national health database to study “whether herd immunity is achieved after reaching a certain percentage of vaccination coverage in Israel”. This provided the small country with accelerated access to vaccines while allowing the pharmaceutical company to compile large amounts of data about the safety and efficacy of its product.
The Three Types of PPG
Published in Robin Stevenson, Learning and Behaviour in Medicine, 2022
When a drug company has a new drug that it wants to promote, it may approach a commercial CME provider in order to support a CME intervention designed to fill a development PPG. In 2019, a US commercial provider won the Innovative Format Award from the Alliance for Continuing Education in the Health Professions for a gamification programme on the treatment of rheumatoid arthritis with a kinase inhibitor. This drug was produced by Pfizer, which had supported the study [26]. Physicians do well to be wary of CME for development PPGs, which may be tackled better by discussion among colleagues and reference to specialist society guidelines.
Direct-to-Consumer Advertising
Published in Charles E. Dean, The Skeptical Professional's Guide to Rational Prescribing, 2022
The FDA has not taken these failures lightly. As Parekh and Shrank have noted,32 the FDA has succeeded in winning multiple lawsuits against Pharma for miscommunicating information in DTCA. In 2012 alone, GlaxoSmithKline paid out $3 billion and Abbott $1.6 billion in penalties. Three years earlier, Eli Lilly paid $1.4 billion, and Pfizer, $2.3 billion in settlements. As I pointed out in Chapter 2, Pharma incurred almost $40 billion in criminal and civil penalties during the years 1991–2017, but this was miniscule compared with $711 billion in net profits made by the 11 largest companies.33
How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned?
Published in Expert Opinion on Drug Discovery, 2022
E. Sila Ozdemir, Srivathsan V. Ranganathan, Ruth Nussinov
Drug repurposing is becoming more and more data driven, as opposed to previous decades when it was mainly retrospective clinical studies based on serendipitous discoveries. One of the famous examples of this is the blockbuster Pfizer drug Viagra, which was repurposed from sildenafil originally developed by researchers to treat cardiovascular diseases [6]. Similarly, other drugs, such as canakinumab (arthiritis drug) [7] and bimatoprost (eye health) [8] were repurposed after patients reported favorable side effects that allowed their usage to treat other diseases. Carbamazepine (Tegretol, epilepsy) is another example. While researchers have understood the molecular underpinning of the effects of these drugs after realizing their repurposing potential, those discoveries are rooted in serendipity and astute observations of the side effects.
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia
Published in Expert Opinion on Emerging Drugs, 2022
David De Bels, Evelyne Maillart, Françoise Van Bambeke, Sebastien Redant, Patrick M. Honoré
Fungal diseases range from relatively-minor superficial and mucosal infections, which represent a large and persistent market, to severe, life-threatening systemic infections, which will probably become more common in a near future. Moreover, delayed diagnosis and treatment can lead to poor patient outcomes and high medical costs. For these reasons, the estimation of Direct Healthcare Costs of Fungal Diseases in the United States are around 7.2 billion dollars per year [65]. The financial evolution of pharmaceutical companies involved in the development of antifungal drugs over the last 5 years as well as the R&D budget will be determinant to bring new drugs on the market. Many promising antifungals never reach the market due to poor recruitment or trial failures, but also because of lack of funding [66]. Antifungal R&D is a dynamic market. Appili Therapeutics Inc. bought ATI-2307 from FUJIFILM Toyama Chemical Co. Ltd. in 2019. Pfizer has just bought in April 2021 Amplyx Pharmaceuticals, Inc. which was developing the first-in-class drug Fosmanogepix. Mycovia Pharmaceuticals was created in 2018 when NovaQuest bought Viamet Pharmaceuticals involved in the search of new tetrazoles like quilseconazole or VT-1129, oteseconazole or VT-1161, and VT-1598. Table 2 summarizes the evolution of the financial status of companies having important research on antifungal drugs currently in clinical development. When available, these financial data show an increase in financial over the last five years especially when clinical trials demonstrate an efficacy of the new drugs.
Acquired hemophilia A after vaccination against SARS-CoV-2 with the mRNA-1273 (Moderna) vaccine
Published in Baylor University Medical Center Proceedings, 2022
Ava Melmed, Andrew Kovoor, Korie Flippo
AHA is an unusual and potentially lethal bleeding diathesis that results from the development of autoantibodies against endogenous Factor VIII, sometimes producing a clinical scenario similar to that of congenital hemophilia A. While it is most typically seen in patients with systemic rheumatic disease, solid and hematologic malignancies, and pregnancy, approximately half of all AHA cases remain idiopathic.1 This condition has rarely been associated with infection with SARS-CoV-2,2 and we have found only a few reports of it being attributed to vaccination against this novel coronavirus.3–6 We believe we have identified an additional case. Our patient was administered the mRNA-1273 version developed by Moderna. The foregoing reports have involved both this vaccine and the one developed by Pfizer-BioNTech.